Your session is about to expire
← Back to Search
VRDN-001 10 mg/kg for Graves' Ophthalmopathy
Study Summary
This trial is for participants who did not respond well to treatment after 15 weeks in two previous studies called THRIVE and THRIVE-2.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants in total are involved in this research investigation?
"Affirmative. Information displayed on clinicaltrials.gov reveals that this medical investigation is actively seeking volunteers. The trial was originally posted on February 1st, 2023 and last updated on March 5th, 2024. A total of 143 participants are being sought from four locations."
Are there any available slots for patients to participate in this clinical trial?
"Indeed, data on clinicaltrials.gov affirms that this medical investigation is actively seeking eligible participants. Originally shared on February 1st, 2023, the trial received its latest update on March 5th, 2024. The research team aims to recruit a total of 143 patients spread across four distinct sites."
In how many diverse venues is this experimental examination currently being conducted?
"Four active sites participating in this trial are the Neuro-eye Clinical Trials situated in Houston, MACRO Trials, Inc. located in Los Angeles, and The Center for Eye and Facial Plastic Surgery based in Somerset. Additionally, there are four other undisclosed locations involved."
Has the drug VRDN-001 at a dosage of 10 mg/kg received approval from the FDA?
"The safety rating for VRDN-001 at a dosage of 10 mg/kg is considered to be 3 by our experts due to the Phase III nature of the trial, indicating existing efficacy data and robust safety evidence."
Share this study with friends
Copy Link
Messenger